Antihypertensive drug therapy in older patients

Current Opinion in Nephrology and Hypertension

Volumn 10, Issue 2, 2001, Pages 263-269

  Wang, Ji Guang ^a   Staessen, Jan A ^a,b  

^a KU LEUVEN DEPARTMENT OF REHABILITATION SCIENCES   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; AGING; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULSE PRESSURE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; FEMALE; HUMANS; HYPERTENSION; MALE; RISK FACTORS; SYSTOLE;

EID: 0035106928     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200103000-00016     Document Type: Article

References (56)

1. Editorial review. Isolated systolic hypertension in the elderly
2. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients
3. Risks of untreated and treated isolated systolic hypertension in the elderly: Meta-analysis of outcome trials
4. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP)
5. Chinese Trial on Isolated Systolic Hypertension in the Elderly
6. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
7. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives
8. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
9. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPP) randomised trial
10. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study
11. Morbidity and mortality in patients randomised to double-blind treatment with long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertensive Treatment (INSIGHT)
12. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study
13. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
14. The HOPE (Heart Outcomes Prevention Evaluation) study: The design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events
15. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
16. Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: No answer yet
17. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease
18. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis. The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT)
19. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
20. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study
21. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events
22. Comparison of active treatment and placebo for older patients with isolated systolic hypertension
23. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial
24. Randomised trial of treatment of hypertension in elderly patients in primary care
25. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
26. Medical Research Council trial of treatment of hypertension in older adults: Principal results
27. MRC trial of treatment of mild hypertension: Principal results
28. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias
29. Some effects of within-person variability in epidemiological studies
30. Systolic blood pressure as an independent predictor of mortality in the hypertension detection and follow-up program
31. Pulsatile versus steady component of blood pressure: A cross-sectional analysis and a prospective analysis on cardiovascular mortality
32. Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham Study
33. Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial
34. Pulse pressure as a risk factor for cardiovascular events in the MRC Mild Hypertension Trial
35. Pulse pressure. A predictor of long-term cardiovascular mortality in a French male population
36. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction
37. Measures of blood pressure and myocardial infarction in treated hypertensive patients
38. Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function
39. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316 099 white men
40. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context
41. Editorial review: Treatment of hypertension in the elderly
42. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis
43. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials
44. INDANA: A meta-analysis on individual patient data in hypertension. Protocol and preliminary results
45. Protocol for prospective collaborative overviews of major randomized trials of blood-pressurelowering treatments
46. Hypertension in the elderly. Implications and generalizability of randomized trials
47. Blood pressure lowering for the secondary prevention of stroke: Rationale and design for PROGRESS
48. Drug treatment of hypertension in the elderly: A meta-analysis
49. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease
50. Epidemiology of treated, compared to untreated hypertension
51. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review
52. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
53. Effects of ramipril, on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
54. Reactive oxygen species, metallo-proteinases, and plaque stability
55. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
56. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients